Trends in the choice of first line treatment for hormone - responsive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.

被引：3

作者：

D'Alonzo, Alessia

Bighin, Claudia

Puglisi, Fabio

DeLaurentiis, Michelino

Fontana, Andrea

Pugliese, Palma

Arpino, Grazia

Poggio, Francesca

Vaglica, Marina

Dellepiane, Chiara

Blondeaux, Eva

Conte, Benedetta

Cognetti, Francesco

Garrone, Ornella

Pastorino, Simona

Ceppi, Marcello

Del Mastro, Lucia

机构：

[1] Osped Policlin San Martino, Oncol Med, Genoa, Italy

[2] SOC Oncol B, Oncol Med & Prevenz Oncol, Aviano, Italy

[3] Natl Canc Inst Fdn G Pascale, Naples, Italy

[4] Azienda Osped Univ Pisana, Pisa, Italy

[5] AOS Anna, UO Oncol Med, Como, Italy

[6] Univ Naples Federico II, Naples, Italy

[7] Osped Policlin San Martino, Oncol Med, Genoa, Italy

[8] IRCCS Policlin San Martino, Genoa, Italy

[9] Osped Policlin San Martino, Oncol Med 2, Dept Med Oncol, Genoa, Italy

[10] Ist Nazl Tumori Regina Elena, Oncol Med, Rome, Italy

[11] S Croce & Carle Teaching Hosp, Med Oncol, Cuneo, Italy

[12] IRCCS AOU San Martino IST, Oncol Med 2, Dept Med Oncol, Genoa, Italy

[13] Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e13053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e13053

引用

页数：1